In the BPH group, 16 (64.00%) cases were H3K27me3-, but only 9 (36.00%) cases were H3K27me3+, and 56% were hepaCAM+, while 44% were hepaCAM− (Fig. 1b). This evidence concerns the gene HEPACAM and benign prostatic hyperplasia.